Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI   US6295191091

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV).

In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV).

Biota Pharmaceuticals was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Joseph M. Patti, PhD502012President, Chief Executive Officer & Director
Russell H. Plumb MBA, CPA552012Executive Chairman & Chief Financial Officer
Anna Novotney-Barry-2013Vice President-Clinical Development
Simon P. Tucker, PhD--Vice President-Research
John H. Vernachio, PhD-2014Vice President-Preclinical Development
James Charles Fox, PhD632012Lead Independent Director
Geoffrey F. Cox, PhD712012Independent Non-Executive Director
Anne M. VanLent662013Independent Non-Executive Director
Michael R. Dougherty572013Independent Non-Executive Director
John P. Richard, MBA572013Independent Non-Executive Director
Shareholders
NameShares%
East Hill Management Co. LLC 3,123,075 8.89%
Broadfin Capital LLC 2,611,711 7.44%
Senzar Asset Management LLC 1,471,300 4.19%
RA Capital Management LLC 1,403,853 4.00%
Krensavage Asset Management LLC 1,356,652 3.86%
Baker Bros. Advisors LP 863,184 2.46%
Fidelity Management & Research Co. 634,698 1.81%
Renaissance Technologies LLC 565,262 1.61%
BlackRock Fund Advisors 554,680 1.58%
BVF Partners LP 350,776 1.00%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
BLUEBIRD BIO INC
RECEPTOS INC
GENMAB A/S
ZHONGYUAN UNION C..
-
JUNO THERAPEUTICS..
-
NEUROCRINE BIOSCI..
AGIOS PHARMACEUTI..
BEIJING SL PHARMA..
DYAX CORP.
HUALAN BIOLOGICAL..
TONGHUA DONGBAO P..
ULTRAGENYX PHARMA..
-
CHINA BIOLOGIC PR..
CLOVIS ONCOLOGY I..
HALOZYME THERAPEU..
KITE PHARMA INC
Sector Biotechnology & Medical Research
Biota Pharmaceuticals Inc : Connections
SciStem Therapeutics, Inc.
Beacon Street Advisors LLC
Altherx, Inc.
Lakewood-Amedex, Inc.
QUE Oncology, Inc.
AMV Advisors
Cempra Pharmaceuticals, Inc.
Alphavax, Inc.
Zygogen LLC
Altitude Aerospace Interiors Ltd.
Gallus Biopharmaceuticals LLC
Technology Partnership Plc
Shire ViroPharma, Inc.
International AIDS Vaccine Initiative, Inc.
AxoTect, Inc.
Multiple Sclerosis Research Australia Ltd.
Phase4 Partners Ltd.
TTP Group Plc
Altiris Therapeutics, Inc.
The Arthritis Foundation
Georgia Venture Partners LLC
Company contact information
Biota Pharmaceuticals, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.biotapharma.com
© 2015 People , Fundamentals and Ownership